Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694602 · ClinicalTrials.gov registry record
Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II
A clinical trial, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- 8
- Enrollment target
NCT01694602 is a clinical trial that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 8 participants.
The verdict
NCT01694602 has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future development of cancer induced skeletal muscle atrophy. Rationale: The approach is based on the hypothesis that after an oral dose of deuterated 3-methylhistidine (D-3MH), the slope of the terminal portion of the decay curve (\> 12 hours post-dosing) for the tracer/tracee (D-3MH/3MH) in the free 3MH pool is proportional to the rate constant for myofibrillar protein degradation and can be determined from spot urine samples.
Interventions
- BIOLOGICAL (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01694602
The ClinicalTrials.gov registry entry for NCT01694602 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH) is the first listed.
NCT01694602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01694602 about?
NCT01694602 is a clinical study titled "Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II". The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future development of cancer induced skeletal muscle atrophy. Rationale: The approa...
What is the current status of trial NCT01694602?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2012-11. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01694602?
The interventions under investigation include: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01694602?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.